Sun Pharmaceutical Industries Ltd. closed 8.26% below its 52-week high of 1,885.00 rupees, which the company reached on ...

Sun Pharmaceutical Industries Ltd. closed 7.47% short of its 52-week high of 1,869.75 rupees, which the company achieved on ...

Taro Pharmaceutical Industries, a unit of Sun Pharma, is recalling over 17,000 units of an antifungal medication in the US ...

Sun Pharma highlights obesity treatment drugs as a growth driver for India's pharma industry, enhancing access to GLP-1 ...

Sun Pharmaceutical Industries targets mid- to high-single digit topline growth in FY26, focusing on innovative medicines and ...

A revolution in India’s weight-loss market is coming. As Semaglutide’s patent ends in 2026, Sun Pharma, Lupin, Torrent, and ...

Vishal Manchanda, Pharma Analyst at Systematix Group, said that when it comes to investing in the GLP-1 theme, the Indian ...

Obesity treatment drugs to drive pharma industry growth in India. Sun Pharma highlights GLP-1 impact. Innovation & ...

Indian drugmakers, known for their chemistry and prowess in making generics—cheaper copies of innovative drugs—for the world, ...

Sun Pharma’s focus areas involve investing in research and development (R&D) to further build its pipeline of innovative medicines.

The US-Venezuela tensions has turned the spotlight on shares of companies like Indian Oil Corp, Oil India, Sun Pharma, Dr ...

The Class II recall, which began on December 9, addresses potential temporary health consequences from the product.